Literature DB >> 33960005

The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis.

Laura E Dichtel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33960005      PMCID： PMC8463414          DOI： 10.1002/hep.31886

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.298


× No keyword cloud information.
  8 in total

1.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Steven P Marso; Stephen C Bain; Agostino Consoli; Freddy G Eliaschewitz; Esteban Jódar; Lawrence A Leiter; Ildiko Lingvay; Julio Rosenstock; Jochen Seufert; Mark L Warren; Vincent Woo; Oluf Hansen; Anders G Holst; Jonas Pettersson; Tina Vilsbøll
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

Review 2.  MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

Authors:  Michael A Nauck; Juris J Meier
Journal:  Eur J Endocrinol       Date:  2019-12       Impact factor: 6.664

3.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

Authors:  Eduardo Vilar-Gomez; Yadina Martinez-Perez; Luis Calzadilla-Bertot; Ana Torres-Gonzalez; Bienvenido Gra-Oramas; Licet Gonzalez-Fabian; Scott L Friedman; Moises Diago; Manuel Romero-Gomez
Journal:  Gastroenterology       Date:  2015-04-10       Impact factor: 22.682

4.  Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis.

Authors:  Ma Ai Thanda Han; Osama Altayar; Shadi Hamdeh; Varun Takyar; Yaron Rotman; Ohad Etzion; Eric Lefebvre; Rifaat Safadi; Vlad Ratziu; Larry J Prokop; Mohammad Hassan Murad; Mazen Noureddin
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-18       Impact factor: 11.382

5.  Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway.

Authors:  Nitika Arora Gupta; Jamie Mells; Richard M Dunham; Arash Grakoui; Jeffrey Handy; Neeraj Kumar Saxena; Frank A Anania
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

6.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

Authors:  Philip N Newsome; Kristine Buchholtz; Kenneth Cusi; Martin Linder; Takeshi Okanoue; Vlad Ratziu; Arun J Sanyal; Anne-Sophie Sejling; Stephen A Harrison
Journal:  N Engl J Med       Date:  2020-11-13       Impact factor: 91.245

7.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

Authors:  Matthew James Armstrong; Piers Gaunt; Guruprasad P Aithal; Darren Barton; Diana Hull; Richard Parker; Jonathan M Hazlehurst; Kathy Guo; George Abouda; Mark A Aldersley; Deborah Stocken; Stephen C Gough; Jeremy W Tomlinson; Rachel M Brown; Stefan G Hübscher; Philip N Newsome
Journal:  Lancet       Date:  2015-11-20       Impact factor: 79.321
  8 in total
  2 in total

Review 1.  Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis.

Authors:  Yong-Yu Yang; Li Xie; Ning-Ping Zhang; Da Zhou; Tao-Tao Liu; Jian Wu
Journal:  Acta Pharmacol Sin       Date:  2022-02-21       Impact factor: 7.169

2.  Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.

Authors:  Peter P Toth; Gregory G Schwartz; Stephen J Nicholls; Aziz Khan; Michael Szarek; Henry N Ginsberg; Jan O Johansson; Kamyar Kalantar-Zadeh; Ewelina Kulikowski; Ken Lebioda; Norman C W Wong; Michael Sweeney; Kausik K Ray
Journal:  Am J Prev Cardiol       Date:  2022-08-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.